Ketamine depot - Alar Pharmaceuticals
Alternative Names: ALA-3000; Depot ketamine formulation - Alar PharmaceuticalsLatest Information Update: 21 Aug 2026
At a glance
- Originator Alar Pharmaceuticals
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
- Mechanism of Action AMPA receptor agonists; Biogenic amine uptake modulators; Dopamine receptor agonists; Nicotinic receptor modulators; NMDA receptor antagonists; Opioid receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Treatment-resistant depressive disorder
- Preclinical Fibromyalgia
Most Recent Events
- 12 Aug 2026 Preclinical trials in Fibromyalgia in Taiwan (unspecified route) (Alar Pharmaceuticals pipeline, August 2026)
- 07 Apr 2026 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Treatment resistant depressive disorder released by Alar Pharmaceuticals
- 30 Dec 2025 Alar Pharmaceuticals completes a phase I trial in Treatment resistant depressive disorders in USA (SC) (NCT06965569)